Stonvex publishes market data and research only. Not investment advice. Not a registered investment advisor. Read disclaimer.

ASND

Live52w high -5.2%

Core line items from ASND's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

Entity: Ascendis Pharma A/S·Source: SEC EDGAR companyfacts·Reported in EUR

Metric	Annual 2025 2025-12-31	Annual 2024 2024-12-31	Annual 2023 2023-12-31	Annual 2022 2022-12-31
Revenue	€720.13M	€363.64M	€266.72M	€51.17M
Operating Income	€-136.27M	€-278.76M	€-455.54M	€-561.81M
Net Income	€-228.03M	€-378.08M	€-481.45M	€-583.19M
EPS (Diluted)	€-3.76	€-6.53	€-8.55	€-10.40
Total Assets	€1.30B	€1.18B	€825.59M	€1.09B
Total Liabilities	€1.47B	€1.29B	€971.28M	€826.39M
Cash & Equivalents	€616.04M	€559.54M	€392.16M	€444.77M
Free Cash Flow OCF − CapEx	Not available	Not available	€-469.80M	€-510.19M
Shares Outstanding	61.98M	60.69M	57.71M	57.15M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data.

Core line items from ASND's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.

52w high -5.2%

Entity: Ascendis Pharma A/S·Source: SEC EDGAR companyfacts·Reported in EUR

Metric	Annual 2025 2025-12-31	Annual 2024 2024-12-31	Annual 2023 2023-12-31	Annual 2022 2022-12-31
Revenue	€720.13M	€363.64M	€266.72M	€51.17M
Operating Income	€-136.27M	€-278.76M	€-455.54M	€-561.81M
Net Income	€-228.03M	€-378.08M	€-481.45M	€-583.19M
EPS (Diluted)	€-3.76	€-6.53	€-8.55	€-10.40
Total Assets	€1.30B	€1.18B	€825.59M	€1.09B
Total Liabilities	€1.47B	€1.29B	€971.28M	€826.39M
Cash & Equivalents	€616.04M	€559.54M	€392.16M	€444.77M
Free Cash Flow OCF − CapEx	Not available	Not available	€-469.80M	€-510.19M
Shares Outstanding	61.98M	60.69M	57.71M	57.15M

Financial data is sourced from public SEC filings where available. Some metrics may be unavailable without premium market data.